Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
American Academy of Sleep Medicine (2014) International classification of sleep disorders, 3. Aufl. American Academy of Sleep Medicine, Darien
Anonym (2007) Zolpidem (Stilnox u. a.): Schlafwandeln, „Schlafessen“ und „Schlaffahren“. Arzneitelegramm 38:31–32
Arzneimittelkommission der deutschen Ärzteschaft (2019) Stellungnahme zu Melatonin (Schlafstörungen bei Kindern und Jugendlichen mit Autismus-Spektrum-Störung und/oder Smith-Magenis-Syndrom), Nr. 750, A19-04, Version 1.0. https://www.akdae.de/Stellungnahmen/AMNOG/A-Z/Melatonin/index.html (Erstellt: 11. Apr. 2019)
Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL (2016) Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Med Rev 34:10–22
Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, Ford I (2005) Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 9:41–50
Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Baker G, Klassen TP, Vohra S (2005) The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 20:1151–1158
Cheng P, Kalmbach DA, Tallent G, Joseph CL, Espie CA, Drake CL (2019) Depression prevention via digital cognitive behavioral therapy for insomnia: a randomized controlled trial. Sleep 42:zsz150
Crestani F, Martin JR, Möhler H, Rudolph U (2000) Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol 131:1251–1254
Dündar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T (2004) Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol 19:305–322
European Medicines Agency (2007) Circadin. Europäischer öffentlicher Beurteilungsbericht (EPAR). http://www.emea.europa.eu/humandocs/PDFs/EPAR/circadin/H-695-en6.pdf
Farkas RH, Unger EF, Temple R (2013) Zolpidem and driving impairment – identifying persons at risk. N Engl J Med 369:689–691
Food and Drug Administration (2019) FDA adds Boxed Warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines. FDA Drug Safety Communication. https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-boxed-warning-risk-serious-injuries-caused-sleepwalking-certain-prescription-insomnia
Garcia-Borreguero D, Cano-Pumarega I (2017) New concepts in the management of restless legs syndrome. BMJ 356:j104. https://doi.org/10.1136/bmj.j104
Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE (2005) Sedative hypnotics in older people with insomnia : meta-analysis of risks and benefits. Br Med J 331:1169
Glass JR, Sproule BA, Herrmann N, Streiner D, Busto UE (2003) Acute pharmacological effects of temazepam, diphenhydramine, and valerian in healthy elderly subjects. J Clin Psychopharmacol 23:260–268
Hajak G, Müller WE, Wittchen HU, Pittrow D, Kirch W (2003) Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 98:1371–1378
Herxheimer A (2005) Jet lag. Clin Evid 13:2178–2183
Hoffmann F, Glaeske G (2014) Benzodiazepinhypnotika, Zolpidem und Zopiclon auf Privatrezept. Verbrauch zwischen 1993 und 2012. Nervenarzt 85:1402–1409
Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN (2012) Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ 17(345):e8343
Ivgy-May N, Hajak G, van Osta G, Braat S, Chang Q, Roth T (2020) Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study, and open-label extension. J Clin Sleep Med. https://doi.org/10.5664/jcsm.8526
Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW (2004) Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch Intern Med 164:1888–1896
Jordan AS, McSharry DG, Malhotra A (2014) Adult obstructive sleep apnoea. Lancet 383:736–747
Klotz U (1995) Benzodiazepin-Hypnotika; Pharmakokinetik. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuropsychopharmaka, Bd. 2. Springer, Wien, S 135–139
Kripke DF (2016) Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit. F1000Res 5:918. Last updated: 19 May 2016. https://doi.org/10.12688/f1000research.8729.1
Lader M (1987) Clinical pharmacology of benzodiazepines. Ann Rev Med 38:19–28
Lähteenmäki R, Neuvonen PJ, Puustinen J, Vahlberg T, Partinen M, Räihä I, Kivelä SL (2019) Withdrawal from long-term use of zopiclone, zolpidem and temazepam may improve perceived sleep and quality of life in older adults with primary insomnia. Basic Clin Pharmacol Toxicol 124:330–340
Leach MJ, Page AT (2015) Herbal medicine for insomnia: a systematic review and meta-analysis. Sleep Med Rev 24:1–12
Li T, Jiang S, Han M, Yang Z, Lv J, Deng C, Reiter RJ, Yang Y (2019) Exogenous melatonin as a treatment for secondary sleep disorders: A systematic review and meta-analysis. Front Neuroendocrinol 52:22–28
Mattila T, Stoyanova V, Elferink A, Gispen-de Wied C, de Boer A, Wohlfarth T (2011) Insomnia medication: do published studies reflect the complete picture of efficacy and safety? Eur Neuropsychopharmacol 21:500–507
McDonagh MS, Holmes R, Hsu F (2019) Pharmacologic Treatments for Sleep Disorders in Children: A Systematic Review. J Child Neurol 34:237–247
Morin CM, Benca R (2012) Chronic insomnia. Lancet 379:1129–1141
Müller-Oerlinghausen B, Kiebgis GM (2018) Berührung – Warum wir sie brauchen und wie sie uns heilt. Ullstein leben, Berlin. ISBN 978-3-96366-006-1
National Institute for Health and Care Excellence (2015) Hypnotics – Key therapeutic topic. Update information January 2017. nice.org.uk/guidance/ktt6
Ohayon MM (2002) Epidemiology of insomnia: what we know and what we still nee to learn. Sleep Med Rev 6:97–111
Parker A, Beresford B, Dawson V, Elphick H, Fairhurst C, Hewitt C, Scantlebury A, Spiers G, Thomas M, Wright K, Mcdaid C (2019) Oral melatonin for non-respiratory sleep disturbance in children with neurodisabilities: systematic review and meta-analyses. Dev Med Child Neurol 61:880–889
Perlis ML, McCall WV, Krystal AD, Walsh JK (2004) Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry 65:1128–1137
Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD, Clinical Guidelines Committee of the American College of Physicians (2016) Management of chronic insomnia disorder in adults: a clinical practice guideline from the American college of physicians. Ann Intern Med 165:125–133
Randall S, Roehrs TA, Roth T (2012) Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study. Sleep 35:1551–1557
Rémi J, Pollmächer T, Spiegelhalder K, Trenkwalder C, Young P (2019) Schlafbezogene Erkrankungen in Neurologie und Psychiatrie. Dtsch Arztebl 116:681–688
Riemann D, Hajak G (2009a) Insomnien. I. Ätiologie, Pathophysiologie und Diagnostik. Nervenarzt 80:1060–1069
Riemann D, Hajak G (2009b) Insomnien. II. Pharmakologische und psychotherapeutische Behandlungsmöglichkeiten. Nervenarzt 80:1327–1340
Riemann D, Baum E, Cohrs S, Crönlein T, Hajak G, Hertenstein E, Klose P, Langhorst J, Mayer G, Nissen C, Pollmächer T, Rabstein S, Schlarb A, Sitter H, Weeß HG, Wetter T, Spiegelhalder K (2017) S3-Leitlinie Nicht erholsamer Schlaf/Schlafstörungen, Kapitel „Insomnie bei Erwachsenen“ (AWMF-Registernummer 063-003), Update 2016. Somnologie 21:2–44
Riemann D, Krone LB, Wulff K, Nissen C (2020) Sleep, insomnia, and depression. Neuropsychopharmacology 45:74–89
Roehrs TA, Randall S, Harris E, Maan R, Roth T (2012) Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study. J Psychopharmacol 26:1088–1095
Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, Filippov G, LoPresti A, Moline M (2019) Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Netw Open 2:e1918254
Rösner S, Englbrecht C, Wehrle R, Hajak G, Soyka M (2018) Eszopiclone for insomnia. Cochrane Database Syst Rev 10:CD10703
Sack RL (2010) Clinical practice. Jet lag. N Engl J Med 362:440–447
Sarris J, Byrne GJ (2011) A systematic review of insomnia and complementary medicine. Sleep Med Rev 15:99–106
Schlack R, Hapke U, Maske U, Busch M, Cohrs S (2013) Häufigkeit und Verteilung von Schlafproblemen und Insomnie in der deutschen Erwachsenenbevölkerung. Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56:740–748
Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M (2008) Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 4:487–504
Shen J, Chung SA, Kayumov L, Moller H, Hossain N, Wang X et al (2006) Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. Can J Psychiatry 51:27–34
Sowa NA (2016) Idiopathic hypersomnia and hypersomnolence disorder: a systematic review of the literature. Psychosomatics 57:152–164
Stiftung Warentest (2017) Medikamente im Test. 9.000 Arzneimittel geprüft und bewertet. ISBN 978-3-86851-167-3
Tröbitscher N (2019) Melatonin: Rechtslage ungewiss. https://www.apotheke-adhoc.de/nachrichten/detail/apothekenpraxis/melatonin-rechtslage-ungewiss-arzneimittel-oder-lebensmittel/
Walsh JK, Roth T, Randazzo A, Erman M, Jamieson A, Scharf M, Schweitzer PK, Ware JC (2000) Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 23:1087–1096
Weich S, Pearce HL, Croft P, Singh S, Crome I, Bashford J, Frisher M (2014) Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ. https://doi.org/10.1136/bmj.g1996
Wilt TJ, MacDonald R, Brasure M, Olson CM, Carlyle M, Fuchs E, Khawaja IS, Diem S, Koffel E, Ouellette J, Butler M, Kane RL (2016) Pharmacologic treatment of insomnia disorder: An evidence report for a clinical practice guideline by the American College of Physicians. Ann Intern Med 165(103):112
Winkelman JW (2015) Insomnia disorder. N Engl J Med 373:1437–1444
Winkler A, Auer C, Doering BK, Rief W (2014) Drug Treatment of Primary Insomnia: A Meta-Analysis of Polysomnographic Randomized Controlled Trials. CNS Drugs 28:799–816
Yeung WF, Chung KF, Yung KP, Ng TH (2015) Doxepin for insomnia: a systematic review of randomized placebo-controlled trials. Sleep Med Rev 19:75–83
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Der/die Herausgeber bzw. der/die Autor(en), exklusiv lizenziert durch Springer-Verlag GmbH, DE, ein Teil von Springer Nature
About this chapter
Cite this chapter
Lohse, M.J. (2020). Hypnotika und Sedativa. In: Schwabe, U., Ludwig, WD. (eds) Arzneiverordnungs-Report 2020. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-62168-4_27
Download citation
DOI: https://doi.org/10.1007/978-3-662-62168-4_27
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-62167-7
Online ISBN: 978-3-662-62168-4
eBook Packages: Medicine (German Language)